Evaxion A/S Reports Q2 2025 Financials and Strategic Progress

Evaxion Biotech ( (EVAX) ) has shared an announcement.

On August 14, 2025, Evaxion A/S announced a business update and second quarter 2025 financial results, highlighting significant achievements and strategic developments. The company reported the completion of patient treatment in its phase 2 trial for the personalized cancer vaccine EVX-01, with plans to present two-year clinical efficacy data at the ESMO Congress in October 2025. Additionally, Evaxion received a grant from the Gates Foundation to develop a new polio vaccine and expanded its R&D pipeline with a new vaccine program against Group A Streptococcus. Financially, Evaxion improved its position by converting debt into equity through an agreement with the European Investment Bank, enhancing its equity by $4.1 million. Despite a net loss of $4.8 million for the quarter, the company reported a solid cash position, sufficient to fund operations until mid-2026.

The most recent analyst rating on (EVAX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Evaxion Biotech stock, see the EVAX Stock Forecast page.

Spark’s Take on EVAX Stock

According to Spark, TipRanks’ AI Analyst, EVAX is a Neutral.

Evaxion Biotech’s overall stock score is influenced primarily by its financial instability despite strong revenue growth. The positive sentiment from the earnings call and technical indicators provide some balance, but the negative valuation and financial challenges weigh heavily on the score.

To see Spark’s full report on EVAX stock, click here.

More about Evaxion Biotech

Evaxion A/S is a clinical-stage TechBio company based in Denmark, specializing in the development of AI-Immunology™ powered vaccines. The company focuses on creating personalized cancer vaccines and vaccines for infectious diseases, leveraging its AI platform to target over 100 different diseases.

Average Trading Volume: 115,065

Technical Sentiment Signal: Sell

Current Market Cap: $4M

See more data about EVAX stock on TipRanks’ Stock Analysis page.